Revolutionizing PDAC Treatment: Exploring the Potential of CTC Detection

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent kind of pancreatic cancer, which is highly aggressive and responds poorly to traditional therapy. Circulating tumor cells (CTCs), detectable in the peripheral blood (PB) of patients with various tumors, share similar genetic and functional properties with the primary tumor, and are closely associated with distant metastasis. The study of CTCs offers valuable insights into tumor heterogeneity, metastatic potential and even treatment resistance, which are crucial for advancing understanding of PDAC. In this paper, we provide a concise overview of the molecular biology of CTCs, the techniques for their enrichment and detection, and an analysis of the clinical utility of CTCs detection in the context of PDAC. The current reliance on epithelial cell markers for CTCs assays has proven insufficient for ensuring the reproducibility of CTCs data. Moreover, the heterogeneity of CTCs is a significant factor that contributes to the variability in clinical outcomes. We anticipate that the in-depth exploration of CTCs characteristics is essential for the accurate identification of specific subgroups of CTCs that contribute to metastasis in the future and provide novel options for the treatment of PDAC. This paper aims to bridge the existing gaps in the literature and to chart a course for future research that could transform the management of PDAC through the innovative use of CTCs.